Diagnostic Kits/Testing new ground: Difference between revisions
Jump to navigation
Jump to search
(New page: * Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoverie...) |
No edit summary |
||
| Line 1: | Line 1: | ||
Hoag, H., 2004. Testing new ground. Nature, 429(6992), 682-3 (http://www.ncbi.nlm.nih.gov/pubmed/15190358) | |||
* Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics. | * Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics. | ||
* Biomarkers may be indicators of disease as well as potential drug targets | * Biomarkers may be indicators of disease as well as potential drug targets | ||
* Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B? (actually an over-optimistic estimate) | * Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B? (actually an over-optimistic estimate) | ||
Revision as of 11:22, 24 September 2009
Hoag, H., 2004. Testing new ground. Nature, 429(6992), 682-3 (http://www.ncbi.nlm.nih.gov/pubmed/15190358)
- Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics.
- Biomarkers may be indicators of disease as well as potential drug targets
- Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B? (actually an over-optimistic estimate)